Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/245188
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Ocaña, Alberto | - |
dc.contributor.author | García-Alonso, Sara | - |
dc.contributor.author | Amir, Eitan | - |
dc.contributor.author | Pandiella, Atanasio | - |
dc.date.accessioned | 2021-07-02T14:20:09Z | - |
dc.date.available | 2021-07-02T14:20:09Z | - |
dc.date.issued | 2018-11 | - |
dc.identifier.citation | Trends in Pharmacological Sciences 39(11): 922-925 (2018) | - |
dc.identifier.issn | 1873-3735 | - |
dc.identifier.uri | http://hdl.handle.net/10261/245188 | - |
dc.description.abstract | The failure rate of development of new drugs in oncology is high, with up to 95% of drugs tested in Phase I not reaching the market. Causes behind this high failure rate are discussed here, and solutions to increase the success in the development of antitumor drugs are suggested. | - |
dc.description.sponsorship | This work was supported by the Ministry of Economy and Competitiveness of Spain (BFU2015-71371-R to A.P. and BES-2013-065223 to S.G.A.); the Junta de Castilla y León (CSI002U16); the scientific foundation of the AECC and the CRIS Foundation (to A.P.). Work in A.O.’s laboratory is supported by the Instituto de Salud Carlos III (PI16/01121); ACEPAIN; Diputación de Albacete; and the CRIS Cancer Foundation (to A.O.). | - |
dc.language | eng | - |
dc.publisher | Cell Press | - |
dc.relation | info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/BFU2015-71371-R | - |
dc.rights | closedAccess | - |
dc.subject | Drug development | - |
dc.subject | Oncology | - |
dc.title | Refining Early Antitumoral Drug Development | - |
dc.type | artículo | - |
dc.identifier.doi | 10.1016/j.tips.2018.09.003 | - |
dc.relation.publisherversion | http://dx.doi.org/10.1016/j.tips.2018.09.003 | - |
dc.date.updated | 2021-07-02T14:20:10Z | - |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | - |
dc.contributor.funder | Junta de Castilla y León | - |
dc.contributor.funder | Asociación Española Contra el Cáncer | - |
dc.contributor.funder | Fundación CRIS contra el Cáncer | - |
dc.contributor.funder | Instituto de Salud Carlos III | - |
dc.contributor.funder | Acepain Albacete | - |
dc.contributor.funder | Diputación de Albacete | - |
dc.relation.csic | Sí | - |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100014180 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100003329 | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | artículo | - |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
15
checked on 12-may-2024
WEB OF SCIENCETM
Citations
16
checked on 22-feb-2024
Page view(s)
61
checked on 18-may-2024
Download(s)
14
checked on 18-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.